A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.

Benjamin SpeichFrédérique ChammartinDaniel SmithMarcel P StoecklePatrizia AmicoAnna L EichenbergerBarbara HasseMacé M SchuurmansThomas MüllerMichael TammMichael DickenmannIrene A AbelaAlexandra TrkolaHans H HirschOriol ManuelMatthias CavassiniLars G HemkensMatthias BrielNicolas J MuellerAndri RauchHuldrych F GünthardMichael T KollerHeiner C BucherKatharina Kusejkonull null

Published in: Trials (2021)

ClinicalTrials.gov NCT04805125 . Registered on March 18, 2021.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
ejection fraction
chronic kidney disease
newly diagnosed
randomized controlled trial
respiratory syndrome coronavirus
study protocol
prognostic factors
clinical trial
peritoneal dialysis
high throughput
phase iii